Eli Lilly CapEx decreased by 8.7% to $2.33B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 54.0%, from $1.51B to $2.33B. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 56.4% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $381.30M | $336.80M | $291.40M | $365.40M | $371.00M | $617.20M | $500.70M | $668.50M | $738.20M | $970.30M | $1.07B | $986.30M | $1.22B | $1.35B | $1.50B | $1.51B | $1.70B | $2.09B | $2.55B | $2.33B |
| QoQ Change | — | -11.7% | -13.5% | +25.4% | +1.5% | +66.4% | -18.9% | +33.5% | +10.4% | +31.4% | +10.4% | -7.9% | +24.2% | +10.3% | +10.8% | +0.9% | +12.4% | +23.1% | +22.0% | -8.7% |
| YoY Change | — | — | — | — | -2.7% | +83.3% | +71.8% | +83.0% | +99.0% | +57.2% | +113.9% | +47.5% | +65.9% | +39.2% | +39.7% | +53.1% | +38.5% | +54.6% | +70.2% | +54.0% |